# Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

> **NCT03988842** · PHASE4 · TERMINATED · sponsor: **Victor Tapson, MD** · enrollment: 4 (actual)

## Conditions studied

- Pulmonary Embolism With Acute Cor Pulmonale
- Pulmonary Embolism
- Pulmonary Embolism With Pulmonary Infarction
- Pulmonary Embolism Subacute Massive
- Right Ventricular Dysfunction
- Right Ventricular Failure

## Interventions

- **DRUG:** Alteplase
- **DRUG:** Unfractionated heparin
- **DRUG:** Placebo
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT03988842
- **Lead sponsor:** Victor Tapson, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-25
- **Primary completion:** 2020-04-05
- **Final completion:** 2020-04-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** COVID-19 pandemic
- **Last updated:** 2021-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03988842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03988842, "Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT03988842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*